Biosimilars require scientifi cally reliable comparative clinical data

Revista Brasileira de Reumatologia

Volumn 53, Issue 1, 2013, Pages 127-131

  Azevedo, Valderílio Feijó ^a,b  

^a PONTIFICAL CATHOLIC UNIVERSITY OF PARANÁ   (Brazil)

^b FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

BIOSIMILAR AGENT; GENERIC DRUG; PLACEBO; RECOMBINANT ERYTHROPOIETIN; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

BIOLOGICAL THERAPY; CLINICAL PRACTICE; CLINICAL RESEARCH; CLINICAL STUDY; COMPARATIVE STUDY; DRUG COST; DRUG EFFICACY; DRUG MANUFACTURE; DRUG PACKAGING; DRUG RESEARCH; DRUG SAFETY; HUMAN; LETTER; PATENT; PROTECTION; QUALITY CONTROL; RELIABILITY; RHEUMATOID ARTHRITIS; SPONDYLARTHRITIS; CLINICAL TRIAL (TOPIC); STANDARD; STATISTICS; ARTHRITIS, RHEUMATOID; STANDARDS; STATISTICS AND NUMERICAL DATA;

ARTHRITIS, RHEUMATOID; BIOSIMILAR PHARMACEUTICALS; CLINICAL TRIALS AS TOPIC; HUMANS;

EID: 84876470598     PISSN: 04825004     EISSN: None     Source Type: Journal    
DOI: 10.1590/S0482-50042013000100013     Document Type: Letter

References (10)

1. Azevedo VF, Felippe LR, Machado DM. Opinião de uma amostra de reumatologistas brasileiros sobre biossimilares. Rev Bras Reumatol 2011; 51(6):.662-71.
2. World Health Organization. Guidelines on Evaluation of Similar Biotherapeutic Products (SBPs), 2010. Available from: http://www.who.int/biologicals/areas/biological_therapeutics/BIOTHERAPEUTICS_FOR_WEB_22APRIL2010.pdf
3. Expert committee on biological standardization Geneva, 19 to 23 October 2009. Guidelines on evaluation of Similar Biotherapeutic Products (SBPs).Adopted by the 60th meeting of the WHO Expert Committee on Biological Standardization.
4. ANVISA. Registro de Produtos Biológicos. Baes Legais e Guias - Coletânea. Resolução - RDC n 55, de 16 de dezembro de 2010. Available from: http://portal.anvisa.gov.br/wps/wcm/connect/935aed0048bd2755a7cdaf9a6e94f0d0/Registro_Produtos_Biologicos_Hemoterapicos_10102011_WEB.pdf?MOD=AJPERES.
5. Castanheira LG, Barbano DB, Rech N. Current development in regulation of similar biotherapeutic products in Brazil. Biologicals; 2011; 39(5):308-11.
6. Fletcher MP. Biosimilars clinical development program: confirmatory clinical trials: a virtual/simulated case study comparing equivalence and non-inferiority approaches. Biologicals 2011; 39(5):270-7.
7. Njue C. Statistical considerations for confi rmatory clinical trials for similar biotherapeutic products. Biologicals 2011; 39(5):266-9.
8. Piaggio G, Elbourne DR, Altman DG, Pocock SJ, Evans SJ, CONSORT Group. Reporting of non inferiority and equivalence randomized trials: an extension of the CONSORT statement. JAMA 2006; 295:1152-60.
9. Chow SC, Shao J, Wang H. Sample size calculations in clinical research. 2. ed. Boca Raton: Chapman & Hall/CRC Biostatistical series; 2008.
10. Bio-Manguinhos, Fundação Oswaldo Cruz. Eritropoietina Humana Recombinante - Monografia do produto. Available from: http://www.fi ocruz.br/bio_eng/media/monografi a_epo.pdf. Accessed on Feb 28, 2012.